SEC Form SC 13G filed by Ambrx Biopharma Inc.

3/16/23 4:05:56 PM ET

$AMAM

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $AMAM alert in real time by email

SC 13G 1 tm239764d1_sc13g.htm SC 13G

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

Ambrx Biopharma Inc.

(Name of Issuer)

Ordinary shares, $0.0001 par value per share

(Title of Class of Securities)

02290A102⁽¹⁾

(CUSIP Number)

March 6, 2023

(Date of Event Which Requires Filing of this Statement)

Check the following box to designate the rule pursuant to which the Schedule is filed:

¨	Rule 13d-1(b)
x	Rule 13d-1(c)
¨	Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

¹ The CUSIP reported herein applies to the Issuer’s American Depositary Shares (“ADS”), each representing seven ordinary shares.

CUSIP No. 02290A102
	1.	Names of Reporting Persons D. E. Shaw Valence Portfolios, L.L.C.
	2.	Check the Appropriate Box if a Member of a Group (See Instructions)
		(a)	¨
		(b)	¨
	3.	SEC Use Only
	4.	Citizenship or Place of Organization Delaware
Number of Shares Beneficially Owned by Each Reporting Person With			5.	Sole Voting Power -0-
			6.	Shared Voting Power 16,537,500⁽²⁾
			7.	Sole Dispositive Power -0-
			8.	Shared Dispositive Power 16,537,500⁽²⁾
	9.	Aggregate Amount Beneficially Owned by Each Reporting Person 16,537,500⁽²⁾
	10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
	11.	Percent of Class Represented by Amount in Row (9) 6.1%⁽³⁾
	12.	Type of Reporting Person (See Instructions) OO

² The number of shares beneficially owned consists of ordinary shares represented by ADS.

³ Based upon 270,328,483 ordinary shares outstanding as of June 30, 2022, as reported in Exhibit 99.1 of the Issuer’s August 29, 2022 Form 6-K.

CUSIP No. 02290A102
	1.	Names of Reporting Persons D. E. Shaw & Co., L.L.C.
	2.	Check the Appropriate Box if a Member of a Group (See Instructions)
		(a)	¨
		(b)	¨
	3.	SEC Use Only
	4.	Citizenship or Place of Organization Delaware
Number of Shares Beneficially Owned by Each Reporting Person With			5.	Sole Voting Power -0-
			6.	Shared Voting Power 22,050,000⁽²⁾
			7.	Sole Dispositive Power -0-
			8.	Shared Dispositive Power 22,050,000⁽²⁾
	9.	Aggregate Amount Beneficially Owned by Each Reporting Person 22,050,000⁽²⁾
	10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
	11.	Percent of Class Represented by Amount in Row (9) 8.2%⁽³⁾
	12.	Type of Reporting Person (See Instructions) OO

² The number of shares beneficially owned consists of ordinary shares represented by ADS.

³ Based upon 270,328,483 ordinary shares outstanding as of June 30, 2022, as reported in Exhibit 99.1 of the Issuer’s August 29, 2022 Form 6-K.

CUSIP No. 02290A102
	1.	Names of Reporting Persons D. E. Shaw & Co., L.P.
	2.	Check the Appropriate Box if a Member of a Group (See Instructions)
		(a)	¨
		(b)	¨
	3.	SEC Use Only
	4.	Citizenship or Place of Organization Delaware
Number of Shares Beneficially Owned by Each Reporting Person With			5.	Sole Voting Power -0-
			6.	Shared Voting Power 22,050,000⁽²⁾
			7.	Sole Dispositive Power -0-
			8.	Shared Dispositive Power 22,050,000⁽²⁾
	9.	Aggregate Amount Beneficially Owned by Each Reporting Person 22,050,000⁽²⁾
	10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
	11.	Percent of Class Represented by Amount in Row (9) 8.2%⁽³⁾
	12.	Type of Reporting Person (See Instructions) IA, PN

² The number of shares beneficially owned consists of ordinary shares represented by ADS.

³ Based upon 270,328,483 ordinary shares outstanding as of June 30, 2022, as reported in Exhibit 99.1 of the Issuer’s August 29, 2022 Form 6-K.

CUSIP No. 02290A102
	1.	Names of Reporting Persons David E. Shaw
	2.	Check the Appropriate Box if a Member of a Group (See Instructions)
		(a)	¨
		(b)	¨
	3.	SEC Use Only
	4.	Citizenship or Place of Organization United States
Number of Shares Beneficially Owned by Each Reporting Person With			5.	Sole Voting Power -0-
			6.	Shared Voting Power 22,050,000⁽²⁾
			7.	Sole Dispositive Power -0-
			8.	Shared Dispositive Power 22,050,000⁽²⁾
	9.	Aggregate Amount Beneficially Owned by Each Reporting Person 22,050,000⁽²⁾
	10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
	11.	Percent of Class Represented by Amount in Row (9) 8.2%⁽³⁾
	12.	Type of Reporting Person (See Instructions) IN

² The number of shares beneficially owned consists of ordinary shares represented by ADS.

³ Based upon 270,328,483 ordinary shares outstanding as of June 30, 2022, as reported in Exhibit 99.1 of the Issuer’s August 29, 2022 Form 6-K.

Item 1.
	(a)	Name of Issuer
		Ambrx Biopharma Inc.

	(b)	Address of Issuer's Principal Executive Offices
		10975 Torrey Pines Road La Jolla, California 92037

Item 2.
	(a)	Name of Person Filing
		D. E. Shaw Valence Portfolios, L.L.C. D. E. Shaw & Co., L.L.C. D. E. Shaw & Co., L.P. David E. Shaw

	(b)	Address of Principal Business Office or, if none, Residence
		The business address for each reporting person is: 1166 Avenue of the Americas, 9^th Floor New York, NY 10036

	(c)	Citizenship
		D. E. Shaw Valence Portfolios, L.L.C. is a limited liability company organized under the laws of the state of Delaware. D. E. Shaw & Co., L.L.C. is a limited liability company organized under the laws of the state of Delaware. D. E. Shaw & Co., L.P. is a limited partnership organized under the laws of the state of Delaware. David E. Shaw is a citizen of the United States of America.

	(d)	Title of Class of Securities
		Ordinary shares, $0.0001 par value per share

	(e)	CUSIP Number
		02290A102

Item 3.		If this statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c), check whether the person filing is a:
Not Applicable
Item 4.		Ownership

As of March 6, 2023:

(a)	Amount beneficially owned:

	D. E. Shaw Valence Portfolios, L.L.C.:	16,537,500 shares

	D. E. Shaw & Co., L.L.C.:	22,050,000 shares This is composed of (i) 16,537,500 shares in the name of D. E. Shaw Valence Portfolios, L.L.C. and (ii) 5,512,500 shares in the name of D. E. Shaw Oculus Portfolios, L.L.C.
	D. E. Shaw & Co., L.P.:	22,050,000 shares This is composed of (i) 16,537,500 shares in the name of D. E. Shaw Valence Portfolios, L.L.C. and (ii) 5,512,500 shares in the name of D. E. Shaw Oculus Portfolios, L.L.C.
	David E. Shaw:	22,050,000 shares This is composed of (i) 16,537,500 shares in the name of D. E. Shaw Valence Portfolios, L.L.C. and (ii) 5,512,500 shares in the name of D. E. Shaw Oculus Portfolios, L.L.C.

(b)

Percent of class:

	D. E. Shaw Valence Portfolios, L.L.C.:	6.1%
	D. E. Shaw & Co., L.L.C.:	8.2%
	D. E. Shaw & Co., L.P.:	8.2%
	David E. Shaw:	8.2%

(c)

Number of shares to which the person has:

(i)

Sole power to vote or to direct the vote:

	D. E. Shaw Valence Portfolios, L.L.C.:	-0- shares
	D. E. Shaw & Co., L.L.C.:	-0- shares
	D. E. Shaw & Co., L.P.:	-0- shares
	David E. Shaw:	-0- shares

(ii)

Shared power to vote or to direct the vote:

	D. E. Shaw Valence Portfolios, L.L.C.:	16,537,500 shares
	D. E. Shaw & Co., L.L.C.:	22,050,000 shares
	D. E. Shaw & Co., L.P.:	22,050,000 shares
	David E. Shaw:	22,050,000 shares

(iii)

Sole power to dispose or to direct the disposition of:

	D. E. Shaw Valence Portfolios, L.L.C.:	-0- shares
	D. E. Shaw & Co., L.L.C.:	-0- shares
	D. E. Shaw & Co., L.P.:	-0- shares
	David E. Shaw:	-0- shares

(iv)

Shared power to dispose or to direct the disposition of:

	D. E. Shaw Valence Portfolios, L.L.C.:	16,537,500 shares
	D. E. Shaw & Co., L.L.C.:	22,050,000 shares
	D. E. Shaw & Co., L.P.:	22,050,000 shares
	David E. Shaw:	22,050,000 shares

David E. Shaw does not own any shares directly. By virtue of David E. Shaw’s position as President and sole shareholder of D. E. Shaw & Co., Inc., which is the general partner of D. E. Shaw & Co., L.P., which in turn is the investment adviser of D. E. Shaw Valence Portfolios, L.L.C. and D. E. Shaw Oculus Portfolios, L.L.C., and by virtue of David E. Shaw’s position as President and sole shareholder of D. E. Shaw & Co. II, Inc., which is the managing member of D. E. Shaw & Co., L.L.C., which in turn is the manager of D. E. Shaw Valence Portfolios, L.L.C. and D. E. Shaw Oculus Portfolios, L.L.C., David E. Shaw may be deemed to have the shared power to vote or direct the vote of, and the shared power to dispose or direct the disposition of, the 22,050,000 shares as described above constituting 8.2% of the outstanding shares and, therefore, David E. Shaw may be deemed to be the beneficial owner of such shares. David E. Shaw disclaims beneficial ownership of such 22,050,000 shares.

Item 5.	Ownership of Five Percent or Less of a Class
Not Applicable
Item 6.	Ownership of More than Five Percent on Behalf of Another Person.
Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.
Not Applicable
Item 8.	Identification and Classification of Members of the Group
Not Applicable
Item 9.	Notice of Dissolution of Group
Not Applicable
Item 10.	Certification

By signing below, each of D. E. Shaw Valence Portfolios, L.L.C., D. E. Shaw & Co., L.L.C., D. E. Shaw & Co., L.P., and David E. Shaw certify that, to the best of such reporting person’s knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purposes or effect.

SIGNATURE

After reasonable inquiry and to the best of their knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct. Powers of Attorney, dated March 1, 2017, granted by David E. Shaw in favor of Nathan Thomas, are attached hereto.

Dated: March 16, 2023

	D. E. Shaw Valence Portfolios, L.L.C.

	By:	/s/ Nathan Thomas
		Nathan Thomas
		Authorized Signatory

	D. E. Shaw & Co., L.L.C.

	By:	/s/ Nathan Thomas
		Nathan Thomas
		Authorized Signatory

	D. E. Shaw & Co., L.P.

	By:	/s/ Nathan Thomas
		Nathan Thomas
		Chief Compliance Officer

	David E. Shaw

	By:	/s/ Nathan Thomas
		Nathan Thomas
		Attorney-in-Fact for David E. Shaw

Get the next $AMAM alert in real time by email

Date	Price Target	Rating	Analyst
9/25/2023	$15.00	Mkt Outperform	JMP Securities
9/12/2023	$26.00	Buy	BTIG Research
7/31/2023	$29.00	Outperform	RBC Capital Mkts
6/14/2023	$26.00	Buy	B. Riley Securities
6/2/2023	$30.00	Outperform	Oppenheimer
5/19/2023	$25.00	Overweight	Cantor Fitzgerald
4/7/2022	$16.00	Outperform	Robert W. Baird
2/28/2022	$6.00	Neutral	Goldman Sachs

SEC Form SC 13G filed by Ambrx Biopharma Inc.

Chat with this insight

Recent Analyst Ratings for
$AMAM

$AMAM
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4: Cormorant Asset Management, Lp bought $19,625,601 worth of Ordinary Shares (2,152,738 units at $9.12)

$AMAM
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Hermans Kate

SEC Form 4 filed by Loesberg Janet

O'Connor Daniel J. returned 48,202 shares to the company, closing all direct ownership in the company (SEC Form 4)

$AMAM
Press Releases

Fastest customizable press release news feed in the world

Cartography Announces Appointment of Troy Wilson, Ph.D., J.D., to its Board of Directors

Ambrx Shareholders Approve Acquisition by Johnson & Johnson

Ambrx Announces Sale to Johnson & Johnson

$AMAM
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

JMP Securities initiated coverage on Ambrx Biopharma with a new price target

BTIG Research initiated coverage on Ambrx Biopharma with a new price target

RBC Capital Mkts initiated coverage on Ambrx Biopharma with a new price target

$AMAM
Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G/A filed by Ambrx Biopharma Inc. (Amendment)